To include your compound in the COVID-19 Resource Center, submit it here.

Sellas reports Phase II data for galinpepimut-S in MM

In September, Sellas Life Sciences Group Ltd. (Hamilton, Bermuda) reported data from 20 patients with multiple myeloma (MM) in

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE